8 results found.

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non Clinical Trial using autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma.
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; bortezomib; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma.
alisertib; bortezomib; rituximab; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis